EGM and Trading Update

Dechra Pharmaceuticals PLC
08 January 2008

Issued by Citigate Dewe Rogerson Ltd, Birmingham

Tuesday, 8 January 2008
                                                               Immediate Release


                         Dechra(R) Pharmaceuticals PLC
               Shareholders approve £62 million VetXX acquisition
                                      and
                         Current Trading and Prospects


Dechra Pharmaceuticals PLC ('Dechra' or 'Group') announces that, at today's EGM,
shareholders approved the proposal to acquire VetXX Holding A/S ('VetXX' or the
'Acquisition'), a leading developer, producer and marketer of companion animal
veterinary products.

The value of the transaction is £61.7 million and will be paid in cash on
completion.

Based in Denmark VetXX employs 165 people and operates in ten European countries
(Norway, Denmark, Finland, Sweden, Holland, Spain, Portugal, France, Ireland and
the UK). It also supplies through distributor agreements into other countries,
including Japan and Germany.

The Acquisition accelerates the Group's objective of delivering medium to
long-term growth, through the development of its own branded veterinary
pharmaceutical portfolio of both novel and generic products and the licensing of
these key products into international markets.

The Acquisition is anticipated to be earnings enhancing (before amortisation and
exceptional costs) in the first full year and significantly earnings enhancing
thereafter.

The proxy votes received for the resolutions were as follows:

Resolution                             For      Against   Discretionary    Withheld

 1.  To approve the proposed       34,874,000     nil         10,759        155,859
     acquisition of VetXX

 2.  To increase the authorised    35,029,859     nil         10,759          nil
     ordinary share capital of
     the Company from £750,000 to
     £1,000,000

 3.  To authorise the directors    35,022,859     nil         12,759          5,000
     of the Company for the
     purposes of section 80 of
     the Companies Act 1985 to
     allot relevant securities

 4.  To authorise the directors    34,864,620     nil         13,759        162,239
     of the Company for the
     purposes of section 95 of
     the Companies Act 1985 to
     allot equity securities as
     if section 89(1) of the Act
     did not apply

Completion of the Acquisition is expected to take place on 15 January 2007.
Application has been made to the London Stock Exchange for admission to trading
of the new ordinary shares which is expected to take place at 8.00 a.m. on 9
January 2008.

Commenting, Dechra's Chief Executive, Ian Page said:

'VetXX is a compelling strategic fit and shares a similar business model and
ambition with Dechra's pharmaceuticals division.

'It provides a strong European footprint, materially increases the Group's range
of licensed veterinary pharmaceutical products and establishes a European sales
and distribution network to market the enlarged product range and future
developed products.'

Current Trading and Prospects
In the announcement made on 12 December 2007, the Group provided the following
trading update.

'Since 30 June 2007, Dechra has continued to trade in-line with management's
expectations with revenue for the four months ended 31 October 2007 in the
Pharmaceutical and Services divisions 41.7% and 8.4% ahead of the comparable
prior year periods, respectively. The Board of Dechra is confident in the future
performance of the enlarged Group. The strong current trading of both Dechra and
VetXX will be further enhanced by the enlarged product range and the wider
distribution infrastructure of the enlarged Group. In addition, the long term
process of product development and approval will be enhanced by the broader
knowledge base of the enlarged Group.'

Trading in the last two months of the year ended 31 December 2007 continued to
be in-line with management expectations with overall results for the first six
months in terms of revenue being approximately £140.9 million, 11.9% ahead of
the comparable period last year.

The Directors will provide a further update on its progress to shareholders at
the time of the Group's Interim Results for the six months ended 31 December
2007, scheduled to be announced on Tuesday, 26 February 2008.

Enquiries:

Ian Page, Chief Executive              Fiona Tooley, Director
Simon Evans, Group Finance Director    Keith Gabriel, Senior Account Manager
Dechra Pharmaceuticals PLC             Citigate Dewe Rogerson
Tel: [phone]               Tel: [phone]

Mobile:[phone] (IP)        Mobile: [phone] (FMT)

www.dechra.com

[e-mail]


Editors Notes:

A full copy of the Regulatory News Announcement made on 12 December 2007 can be
found at www.dechra.com . Further information on VetXX can also be found on

www.vetxx.com.

Dechra Pharmaceuticals PLC (LSE Ticker: DPH)

Dechra currently operates under two divisions; Pharmaceuticals and Services.
Both divisions are focused on the veterinary market with a key area of
specialisation being on companion animal products. The Group currently employs
over 760 people across its 17 locations in the UK and USA.

Trade Marks appear throughout this release in italics. Dechra and the Dechra 'D'
logo are registered Trade Marks of Dechra Pharmaceuticals PLC.

VetXX was incorporated in February 2005 to bring together the companion animal
products in Leo Pharmaceuticals A/S. The business was acquired by the business'
management team backed by Montagu Private Equity.

The United Kingdom and France are VetXX's most significant territories, together
representing approximately 45 per cent. of total revenue in the year ended 31
December 2006. In the 11-months to 30 November 2007 total unaudited sales were
£31.8 million, 6% ahead of the corresponding period in 2006 at £30.0 million,
this revenue growth is principally driven by VetXX's Pharmaceutical division.


                      This information is provided by RNS
            The company news service from the London Stock Exchange